Firma Clinical Data Services Group Receives 2017 Small/Medium Enterprise Award

||Firma Clinical Data Services Group Receives 2017 Small/Medium Enterprise Award

Firma Clinical Data Services Group Receives 2017 Small/Medium Enterprise Award

HUNT VALLEY, MARYLAND — NOVEMBER 01, 2017 — Firma Clinical Research, an ISO quality management-certified clinical research organization (CRO), is pleased to announce being awarded the 2017 Outstanding Small and Medium Enterprise award by the Small and Medium Enterprise Administration (SMEA) of the Ministry of Economic Affairs of Taiwan.

Firma’s Data Services group was selected for this award based on its sound management, outstanding performance, and sustainable contribution to society. “I’m honored to accept this award as a result of the hard work and dedication of our Data Services team” noted Eugenia Henry, Ph.D., President, Biostatistics and Data Management Services for Firma. “Applying our specialized services to provide direct client value is what our team members strive to accomplish.”

With recent support for a client CFDA regulatory submission in China, the team members within the Firma Clinical Data Services group have supported their 50th drug regulatory approval submission. “I’m proud of the work our team continues to provide to our clients and ultimately our support of Sponsors in their drug development journey,” notes Henry. “We look forward to continuing to support the submission and approval of new and approved treatments, and in our continued contribution to patients and society.”

About Firma Clinical Research
An ISO 9001:2015 quality-certified organization, Firma Clinical supports the drug development efforts of pharmaceutical and biotech companies through advanced in-home patient visits, data management & biostatistics, medical writing, regulatory consulting, clinical pharmacology, and clinical operations. Built on decades of clinical leadership and expertise, Firma is dedicated to a collaborative approach that accelerates the development of safe and effective treatments for the pharmaceutical, biotechnology, and medical device industries. For more information, please visit

Press Contact: Michael Keens, Chief Operating Officer
Twitter: @FirmaClinical

2017-12-08T19:34:12+00:00November 10th, 2017|Categories: News & Media|Tags: |